NFkB p65 (RelA) Phospho S529 Antibody
Anti-NFKB p65 (Rel A) pS529 Antibody - Western Blot
Western Blot of Anti-NFKB p65 (Rel A) pS529 Antibody
Western Blot of Anti-NFKB p65 pS529 Antibody
Datasheet is currently unavailable. Try again or CONTACT US
Datasheet

NFkB p65 (RelA) Phospho S529 Antibody

Rabbit Polyclonal

100-401-266
100 µL
ELISA, WB, IF
Human
Rabbit
Have a Question? Ask a Specialist
$449.00 /Per Item
Availability: Ships next business day
Shipping info:

$50.00 to US & Canada for most products. Final costs are calculated at checkout.

Description

Background

NFkB was originally identified as a factor that binds to the immunoglobulin kappa light chain enhancer in B cells. It was subsequently found in non-B cells in an inactive cytoplasmic form consisting of NFkB bound to IkB. NFkB was originally identified as a heterodimeric DNA binding protein complex consisting of p65 (RelA) and p50 (NFKB1) subunits. Other identified subunits include p52 (NFKB2), cRel, and RelB. The p65, cRel, and RelB subunits are responsible for transactivation. The p50 and p52 subunits possess DNA binding activity but limited ability to transactivate. p52 has been reported to form transcriptionally active heterodimers with the NFkB subunit p65, similar to p50/p65 heterodimers. Low levels of p52 and p50 homodimers can also exist in cells. The heterodimers of p52/p65 and p50/p65 are regulated by physical inactivation in the cytoplasm by IkB-alpha. IkB-alpha binds to the p65 subunit preventing nuclear localization and DNA binding. Activators mediate a rapid phosphorylation of IkB by IkB kinase (IKK) which results in subsequent ubiquitination and proteolytic degradation. NFkB is then transported to the nucleus, where it activates transcription of target genes through binding to NFkB target sequences within the promoter. The HTLV-I protein Tax can induce constitutive NFkB activation through phosphorylation of both IkB-alpha and IkB-beta. The transforming protein Tax inhibits p53 transcriptional activity through the NFkB signaling pathway, specifically via the p65 (RelA) subunit. Anti-NFkB antibody is ideal for Cell Biology, Nuclear Signaling, Neuroscience and Signal Transduction Research.

Application Note

Anti-phospho NFkB antibody reacts human pS529 p65 and shows minimal reactivity by western blot with non-phosphorylated p65 and minimal reactivity by ELISA against the non-phosphorylated form of the immunizing peptide.  Although not tested, this antibody is likely functional in immunohistochemistry and immunoprecipitation.

Purity/Specificity

Anti-NFkB p65 (RelA) Phospho S529 Antibody was prepared from monospecific antiserum by delipidation and defibrination. This phospho specific polyclonal antibody is specific for phosphorylated pS529 human p65.  Reactivity with non-phosphorylated p65 is minimal. Cross reactivity with pS529 phosphorylated p65 from mouse, rat or other species has not been determined.

Anti-NFKB p65 (Rel A) pS529 (RABBIT) Antibody - 100-401-266
rabbit anti-NFkB p65 pS529 Antibody, rabbit anti-RelA pS529 Antibody, NFKB, nfkb, NF-kB, NF-kappaB, NFkappaB
RELA
ELISA, WB
IF
Human
Rabbit
Phosphorylation
Polyclonal
Antiserum
Peptide
NFkB p65 (Rel A) peptide corresponding to a region near phospho Serine 529 of the human protein conjugated to Keyhole Limpet Hemocyanin (KLH).
Liquid (sterile filtered)
75 mg/mL by Refractometry
None
0.1% (w/v) Sodium Azide
None
Dry Ice
Store NFkB p65 (RelA) Phospho S529 Antibody at -20° C prior to opening. Aliquot contents and freeze at -20° C or below for extended storage. Avoid cycles of freezing and thawing. Centrifuge product if not completely clear after standing at room temperature. This product is stable for several weeks at 4° C as an undiluted liquid. Dilute only prior to immediate use.
Expiration date is one (1) year from date of receipt.
Expression of the prosurvival kinase HCK requires PAX5 and mutated MYD88 signaling in MYD88-driven B-cell lymphomas. Blood Adv ()
Applications
WB, IB, PCA
Suppression of Propionibacterium acnes Infection and the Associated Inflammatory Response by the Antimicrobial Peptide P5 in Mice. PloS One ()
Applications
IF, Confocal Microscopy
Botanical Extracts from Rosehip (Rosa canina), Willow Bark (Salix alba), and Nettle Leaf (Urtica dioica) Suppress IL-1β-Induced NF-κB Activation in Canine Articular Chondrocytes. Evid Based Complement Alternat Med. ()
Applications
WB, IB, PCA; IF, Confocal Microscopy
Anti-inflammatory and anti-catabolic effects of TENDOACTIVE® on human tenocytes in vitro. Histol. Histopathol. ()
Applications
Other
Role of NF-kappaB in flow-induced vascular remodeling. Antioxid. Redox Signal. ()
Applications
Other
The phosphatidylinositol 3-kinase/Akt pathway negatively regulates Nod2-mediated NF-kappaB pathway. Biochem. Pharmacol. ()
Applications
Other
Suppression of NF-kappaB activation by curcumin leads to inhibition of expression of cyclo-oxygenase-2 and matrix metalloproteinase-9 in human articular chondrocytes: Implications for the treatment of osteoarthritis. Biochem. Pharmacol. ()
Applications
Other
Effects of curcumin (diferuloylmethane) on nuclear factor-kB signaling in interleukin-1b-stimulated chondrocytes. Ann NY Acad Sci. ()
Applications
IF, Confocal Microscopy; WB, IB, PCA
Piceatannol inhibits TNF-induced NF-kappaB activation and NF-kappaB-mediated gene expression through suppression of IkappaBalpha kinase and p65 phosphorylation. J Immunol ()
Applications
WB, IB, PCA; IF, Confocal Microscopy

Invalid lot number

If you need help finding your CofA, contact us

This product is for research use only and is not intended for therapeutic or diagnostic applications. Please contact a technical service representative for more information. All products of animal origin manufactured by Rockland Immunochemicals are derived from starting materials of North American origin. Collection was performed in United States Department of Agriculture (USDA) inspected facilities and all materials have been inspected and certified to be free of disease and suitable for exportation. All properties listed are typical characteristics and are not specifications. All suggestions and data are offered in good faith but without guarantee as conditions and methods of use of our products are beyond our control. All claims must be made within 30 days following the date of delivery. The prospective user must determine the suitability of our materials before adopting them on a commercial scale. Suggested uses of our products are not recommendations to use our products in violation of any patent or as a license under any patent of Rockland Immunochemicals, Inc. If you require a commercial license to use this material and do not have one, then return this material, unopened to: Rockland Inc., P.O. BOX 5199, Limerick, Pennsylvania, USA.